Catatonia is a syndrome that encompasses multiple motor signs. It can be the only presenting clinical feature in a patient with underlying multiple neuropsychiatric syndromes. The authors present a case of amisulpiride-induced catatonia, further evaluation suggested neuroleptic malignant syndrome (NMS) and showed the occurrence of temporal lobe epilepsy (TLE) and underlying brain pathology with marked frontoparietal atrophy and periventricular white matter hyperintensities. The pathological substrate of catatonia and its complex association with neuropsychiatric syndromes are discussed.
Adityanjee Sajatovic M, Munshi, KR (2005) Neuropsychiatric sequelae of neuroleptic malignant syndrome. Clin Neuropharmacol28: 197–204.
2.
Baca L Martinelli L (1990) Neuroleptic malignant syndrome : a unique association with a tricyclic antidepressant. Neurology40: 1797–1798.
3.
Benjelloun G Jehel L Abgrall G Pelissolo A Allilaire J (2005) Acute catatonic syndrome after neuroleptic malignant syndrome. Encephale31: 705–709.
4.
Berardi D Amore M Keck PE Troia M Dell’Atti M (1998) Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry44: 748–754.
5.
Caroff SN Mann SC Campbell EC (2000a) Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatric Ann30: 314–321.
6.
Caroff SN Mann SC Keck PE Francis A (2000b) Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol20: 257–259.
7.
Farver DK (2003) Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opin Drug Saf2: 21–35.
8.
Fink M (2001) Treating neuroleptic malignant syndrome as catatonia. J Clin Psychopharmacol21: 121.
9.
Fink M Taylor MA (2001) The many varieties of catatonia. Eur Arch Psychiatry Clin Neurosci251 (Suppl. 1): 18–13.
10.
Gerlach J Peacock L (1995) New antipsychotics: the present status. Int Clin Psychopharmacol10 (Suppl. 3): 39–48.
11.
Gill J Singh H Nugent K (2003) Acute lithium intoxication and neuroleptic malignant syndrome. Pharmacotherapy23: 811–815.
12.
Hasan S Buckley P (1998) Novel antipsychotics and the neuroleptic malignant syndrome; a review and critique. Am J Psychiatry155: 1113–1116.
13.
Heinemann F Assion HJ Hermes G Ehrlich M (1997) Paroxetine-induced neuroleptic malignant syndrome (Article in German). Nervenarzt68: 664–666.
14.
Heyland D Sauve M (1991) Neuroleptic malignant syndrome without the use of Neuroleptics. CMAJ145: 817–819.
15.
Kapur S Langlois X Vinken P Megens AA DeCoster R Andrews JS (2002) The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther302: 1129–1134.
16.
Leucht S (2004) Amisulpride a selective dopamine antagonist and atypical antipsychotic:results of a meta analysis of randomised controlled trials. Int J Neuropsychopharmacol7 (Suppl. 1): S15–S20.
17.
Mendez MF Lipton A (2001) Emergent neuroleptic hypersensitivity as a herald of presenile dementia. J Neuropsychiatry Clin Neurosci13: 347–356.
18.
Osman AA Khurasani MH (1994) Lethal catatonia and neuroleptic malignant syndrome. A dopamine receptor shut down hypothesis. Br J Psychiatry165: 548–550.
19.
Primavera A Fonti A Novello P Roccatagliata G Cocito L (1994) Epileptic seizures in patients with acute catatonic syndrome. J Neurol Neurosurg Psychiatry57: 1419–1422.
20.
Stahl SM (2000) Essential Psychopharmacology, Neuroscientific Basis and Practical Applications, second ed.Cambridge, UK: Cambridge University Press.
21.
Starr MS (1996) The role of dopamine in epilepsy. Synapse22: 159–194.
22.
Supe S Matijevic V Kondic L Alvir D (2006) Series of seizures as a sign of development of recurrent malignant neuroleptic syndrome-a case report. Psychiatr Danub18: 97–101.
23.
Trollor JN Sachdev PS (1999) Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry33: 650–659.
24.
Trollor J Sachdev P (2000) In reply to Dr. Lee “catatonia and non-catatonic NMS”. Aust N Z J Psychiatry34: 877–878.
